欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (5): 537-544.

• 临床药理学 • 上一篇    下一篇

氯法拉滨注射液在白血病患者中的单剂量及多剂量临床药代动力学研究

钱忠莲1,2, 赵立波2, 路瑾3, 朱宝英1,2, 徐佳2,4, 王茜2, 方翼2, 黄静1   

  1. 1贵阳医学院,贵阳 550004,贵阳;
    2北京大学人民医院药剂科,
    3血液科, 北京 100044;
    4徐州医学院,徐州 221004,江苏
  • 收稿日期:2012-11-28 修回日期:2013-04-13 出版日期:2013-05-26 发布日期:2013-05-22
  • 通讯作者: 方翼,男,副主任医师,研究方向:临床药理学。Tel: 010-66583834 E-mail: fygk7000@163.com黄静,副教授,研究方向:药剂学与药动学。Tel: 0851-6908568 E-mail:huangjgy@sohu.com
  • 作者简介:钱忠莲,硕士研究生,研究方向:生物药剂与临床药理学。Tel:0851-6908568 E-mail:qianzhonglians@163.com

Pharmacokinetics of single and multiple doses of Clofarabine for injection in patients with leukemia

QIAN Zhong-lian1,2, ZHAO Li-bo2, LU Jin3, ZHU Bao-ying1,2, XU Jia2,4, WANG Qian2, FANG Yi2, HUANG Jing1   

  1. 1Guiyang Medical College, Guiyang 550004, Guizhou, China;
    2Department of Pharmacy,
    3Department of Hematology,Peking University People's Hospital ,Beijing 100044, China;
    4Xuzhou Medical College, Xuzhou 221004,Jiangsu, China
  • Received:2012-11-28 Revised:2013-04-13 Online:2013-05-26 Published:2013-05-22

摘要: 目的: 研究氯法拉滨注射液单剂量及多剂量静脉滴注的人体药动学过程。方法: 4例白血病患者单剂量恒速静脉滴注氯法拉滨注射液 52 mg·m-2·d-1 ,单剂量试验结束后进入多剂量给药试验, 52 mg·m-2·d-1 ,连续给药 5 d。采用高效液相色谱串联质谱法测定血浆及尿液中氯法拉滨的浓度,并采用DAS药动学软件对试验数据进行处理,求算有关药动学参数。结果: 4例受试者单剂量静脉滴注氯法拉滨注射液后,主要药动学参数分别为Cmax(414±205) μg/L,tmax(3.0±1.4) h,t1/2z(4.4±2.0) h,AUC0-t(2475±659) μg·h·L-1,AUC0-∞(2566±606) μg·h·L-1,CLz(21.2±5.1) L·h-1·m-2,Vz(142±97) L/m2,MRT(0-t) (6.3±2.2) h,Zeta(0.18±0.07) h-1,24 h 平均尿液累积排泄率为(39.53±20.98)%。52 mg·m-2·d-1静脉滴注氯法拉滨注射液,连续给药5 d,第5日达稳态,主要药动学参数为Cmax(581±126) μg/L,tmax(2.0±0.8) h,t1/2z(6.4±3.1) h,AUC0-t(2451±349) μg·h·L-1,AUC0-∞(2603±409) μg·h·L-1,CLz(20.4±3.7) L·h-1·m-2,Vz(187±80) L/m,Zeta(0.13±0.05) h-1,MRT(0-t) (5.1±1.8) h,Css(102.14±14.53) μg/L,蓄积因子R(1.04±0.28),血药浓度波动度DF(576.26±226.89)%。结论: 氯法拉滨注射液静脉滴注给药 52 mg·m-2·d-1 ,连续给药 5 d,药物在体内无蓄积,安全性好。

关键词: 氯法拉滨注射液, 白血病, 药动学, 高效液相色谱串联质谱法

Abstract: AIM: To investigate the pharmacokinetics of Clofarabine for injection with a single and multiple dose administration in patients with acute leukemia.METHODS: 4 patients with acute leukemia received a single dose intravenous of 52 mg·m-2·d-1, and then they are repeatedly administrated with 52 mg·m-2·d-1 Clofarabine for 5 days.The concentrate of Clofarabine in plasma and urine were determined by HPLC-MS/MS.DAS pharmacokinetics software was used for data process and calculation of pharmacokinetic parameters.RESULTS: The main pharmacokinetic parameters of Clofarabine after single dose of 52 mg·m-2·d-1 Clofarabine for injection were as follows: Cmax(414±205) μg/L,tmax(3.0±1.4) h, t1/2z(4.4±2.0) h,AUC0-t(2475±659) μg·h·L-1, AUC0-∞(2566±606) μg·h·L-1, CLz(21.2±5.1) L·h-1·m-2, Vz(142±97) L/m, MRT0-t(6.3±2.2) h, Zeta(0.18±0.07) h-1, the 12 h cumulative urine excretion rate was (39.53±20.98)%, the main pharmacokinetic parameters of Clofarabine after 52 mg·m-2·d-1 for 5 days were as follows: Cmax(581±126) μg/L, tmax(2.0±0.8) h, t1/2z(6.4±3.1) h, AUC0-t(2451±349) μg·h·L-1, AUC0-∞(2603±409) μg·h·L-1, CLz(20.4±3.7) L·h-1·m-2, Vz(187±80) L/m, Zeta(0.13±0.05) h-1, MRT0-24 h(5.1±1.8) h, Css(102.14±14.53) μg/L,the accumulation coefficients R was (1.04±0.28), the fluctuation coefficients of plasma concentration DF was (576.26±226.89)%.CONCLUSION: No accumulation is detected when 52 mg·m-2·d-1 Clofarabine for injection has been administrated for 5 days, it was safe.

Key words: Clofarabine injection, Leukemia, Pharmacokinetics, HPLC-MS/MS

中图分类号: